June. 11, 2020 |
|
July. 20, 2023 |
|
jRCT2080225225 |
A Phase II, long-term, extension study of DS-5141b in Patients With Duchenne Muscular Dystrophy |
|
A Phase II, long-term, extension study of DS-5141b in Patients With Duchenne Muscular Dystrophy |
DAIICHI SANKYO Co.,Ltd. |
||
1-2-58, Hiromachi, Shinagawa-ku, Tokyo |
||
+81-3-6225-1111 |
||
dsclinicaltrial@daiichisankyo.co.jp |
DAIICHI SANKYO Co.,Ltd. |
||
1-2-58, Hiromachi, Shinagawa-ku, Tokyo |
||
+81-3-6225-1111 |
||
dsclinicaltrial@daiichisankyo.co.jp |
completed |
June. 30, 2020 |
||
8 | ||
Interventional |
||
multi-center, open-label extension |
||
treatment purpose |
||
2 |
||
Has competed a study of DS5141-A-J101. |
||
1) Significant safety issues in a study of DS5141-A-J101 |
||
5age old over | ||
No limit | ||
Male |
||
Duchenne muscular dystrophy |
||
investigational material(s) |
||
safety |
||
pharmacokinetics |
DAIICHI SANKYO Co.,Ltd. | |
- |
- | |
- |
Kobe University Hospital Institutional Review Board | |
7-5-2 Kusunokicho, Kobe Chuo-ku, Hyogo, 650-0017, Japan | |
approved | |
April. 27, 2020 |
NCT04433234 | |
ClinicalTrials.gov |
JapicCTI-205321 | |
Japan |